Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
7.49
+0.53 (7.61%)
May 1, 2026, 9:08 AM EDT - Market open
Jaguar Health Employees
Jaguar Health had 47 employees as of December 31, 2025. The number of employees decreased by 2 or -4.08% compared to the previous year.
Employees
47
Change (1Y)
-2
Growth (1Y)
-4.08%
Revenue / Employee
$244,915
Profits / Employee
-$1,139,894
Market Cap
3.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 47 | -2 | -4.08% |
| Dec 31, 2024 | 49 | 0 | - |
| Dec 31, 2023 | 49 | -11 | -18.33% |
| Dec 31, 2022 | 60 | 8 | 15.38% |
| Dec 31, 2021 | 52 | 18 | 52.94% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tivic Health Systems | 52 |
| GeoVax Labs | 17 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Ensysce Biosciences | 10 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| Alzamend Neuro | 6 |
JAGX News
- 2 days ago - Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs - Accesswire
- 4 days ago - Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - Accesswire
- 7 days ago - Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) - Accesswire
- 10 days ago - Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders - Accesswire
- 18 days ago - Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Accesswire
- 21 days ago - Jaguar Health Earnings Call Transcript: Q4 2025 - Transcripts
- 21 days ago - Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - Accesswire
- 23 days ago - Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire